Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.41 |
| ▸ | CDK2 | P24941 | 7/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.40 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680173 | 0.89 | CHEK1 (0.46) | NPC1RAB9ACHEK1CCNA2CDK2 | |
| SCHEMBL15031404 | 0.87 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL20372 | 0.87 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL7875874 | 0.86 | DGAT1 (0.38) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL7881064 | 0.84 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL15007415 | 0.83 | CHEK1 (0.47) | NPC1RAB9ACHEK1CCNA2CDK2 | |
| SCHEMBL610791 | 0.83 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL15031641 | 0.83 | CHEK1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL27225 | 0.83 | CHEK1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL15007025 | 0.83 | CHEK1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | NPC1 348/4885RAB9A 720/4885SMN1; SMN2 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.